학술논문

Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study
Document Type
article
Source
Cancer Causes & Control. 30(11)
Subject
Biomedical and Clinical Sciences
Health Services and Systems
Health Sciences
Oncology and Carcinogenesis
Reproductive Medicine
Aging
Cancer
Rare Diseases
Estrogen
Prevention
Clinical Research
Ovarian Cancer
Uterine Cancer
Aged
Endometrial Neoplasms
Estradiol
Estrogens
Female
Hormone Replacement Therapy
Humans
Middle Aged
Ovarian Neoplasms
Postmenopause
Risk
Endogenous estrogens
Estrogen metabolites
Ovarian cancer
Endometrial cancer
Nested case-control study
Current hormone therapy users
Nested case–control study
Public Health and Health Services
Epidemiology
Oncology and carcinogenesis
Language
Abstract
PurposeMenopausal hormone therapy (MHT) use induces alterations in circulating estrogens/estrogen metabolites, which may contribute to the altered risk of reproductive tract cancers among current users. Thus, the current study assessed associations between circulating estrogens/estrogen metabolites and ovarian and endometrial cancer risk among MHT users.MethodsWe conducted a nested case-control study among postmenopausal women using MHT at baseline in the Women's Health Initiative Observational Study (179 ovarian cancers, 396 controls; 230 endometrial cancers, 253 controls). Multivariable logistic regression was utilized to estimate odds ratios and 95% confidence intervals overall and by subtype.ResultsEstrogen/estrogen metabolite levels were not associated with overall or serous ovarian cancer risk, examined separately. However, unconjugated estradiol was positively associated with non-serous ovarian cancer risk [quintile 5 vs. quintile 1: 3.01 (1.17-7.73); p-trend = 0.03; p-het